Philogen S.p.a., based in Siena, Italy, specializes in the development of innovative immunotherapy antibodies aimed at treating various cancers and inflammatory diseases. The company focuses on advanced therapeutic modalities, leveraging its expertise in TNF-alpha, IL-12, and antibody compositions to create targeted treatments. Philogen's research encompasses critical areas such as immunoconjugates, tumor antigens, and neovasculature, contributing to the understanding and manipulation of angiogenesis for therapeutic benefit.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

50 Patents

#1 in

#183 in

#14,024 in the World

Siena, Italy

Philogen S.p.a.

Forward Citations = 142

62 inventors:

Dario Neri (22 out of 41 patents)

Kathrin Schwager (9 out of 9 patents)

Giovanni Neri (8 out of 9 patents)

4. Sarah Wulhfard (8 out of 8 patents)

5. Alessandra Villa (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Philogen S.p.a.. Retrieved from https://idiyas.com/company/philogen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

11 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

33 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]